Voxeleron at ARVO 2023
Voxeleron at ARVO 2023 An ARVO in April in New Orleans is certainly an exciting prospect, so we look forward to our time in this historic city. Ahead of that, we’re taking the opportunity to share some updates as a year is a long time in the world of…
Orion vs. Cirrus vs. Spectralis
In order to fulfill recruitment goals, large clinical trials must necessarily use images from numerous sites utilizing different imaging vendor systems. For OCT images, limitations in image segmentation with the original equipment manufacturer (OEM) software and differences between the algorithms used by the different OEM software programs can introduce bias…
A Growing IP Portfolio in Further Support of Reading Center Workflows
Within the context of clinical trials, the analysis of optical coherence tomography (OCT) images can be a time consuming process. Data files that can be as large as a Gigabyte must be moved around, anonymized and loaded into different analysis tools depending on the format. Once segmented, the boundaries of…
SOC 2 & 21 CFR Part 11 Announcement
SOC 2 & 21 CFR Part 11 Announcement Voxeleron is now SOC 2 Type 1 certified and in compliance with FDA’s 21 CFR Part 11. Taking excellent care of customer data is our highest priority, and we are invested in implementing security measures that follow all clinical research standards. Achieving…
Fluid Quantification in OCT – A Validation using a Home-Based OCT Device
Voxeleron’s AI Retinal Fluid Quantification Highlighted in Retina Voxeleron is pleased to announce the publication in Retina of our most recent validation paper on AI-based fluid quantification. In this case it is using the RetinaCheck low-cost optical coherence tomography (OCT) device (OCTHealth LLC, Sacramento, California). This prospective study was based…
Eyes on the Prize: Spotlight on AI-Driven Innovations
Eyes on the Prize: Spotlight on AI-Driven Innovations The advancement of artificial intelligence (AI) is driving innovation in ophthalmic research. While there are still challenges to be addressed, there is marked progress in applying AI to improve many aspects of ophthalmic research and trials. In the final part of our…
Eyes on the Prize: Challenges Using AI in Ophthalmology
Eyes on the Prize: Challenges Using AI in Ophthalmology The use of artificial Intelligence (AI) in global healthcare is expected to expand at a compound annual growth rate of 38.4% from 2022 to 2030. While AI is driving compelling innovation across healthcare, including the ophthalmology space, it brings a new…
Eyes on the Prize: The Case for AI in Ophthalmic Clinical Research
Eyes on the Prize: The Case for AI in Ophthalmic Clinical Research The pace of innovation in ophthalmic research continues to advance, yet costly issues with clinical trial recruitment, management and analysis persist. Instead of settling for the status quo, perhaps now is the time to revisit the potential of…
Who Sets the “Standard”? Enabling Interoperability in Ophthalmic Image Analysis
Who Sets the “Standard”? Enabling Interoperability in Ophthalmic Image Analysis Why are standards needed in ophthalmology? The evolution of data science and artificial intelligence has made standards a pressing issue. Ophthalmology has the most imaging technologies and imaging device manufacturers of any field in medicine, and yet most ophthalmic imaging…
Macula Society 45th Annual Meeting
Professor Giovanni Staurenghi presented collaborative work on the “Automated quantitative assessment of neovascular age-related macular degeneration ocular coherence tomography (OCT) images acquired using a home-based OCT device” at today’s session on neovascular AMD. The work details the performance of a prototype home OCT device used to capture 136 subject eyes…
